Claro Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$853K Buy
23,201
+2,282
+11% +$108K 0.1% 167
2025
Q4
$1.06M Sell
20,919
-100
-0.5% -$5.11K 0.15% 123
2025
Q3
$1.17M Sell
21,019
-204
-1% -$11.9K 0.17% 109
2025
Q2
$1.46M Sell
21,223
-162
-0.8% -$11K 0.24% 87
2025
Q1
$1.48M Buy
21,385
+113
+0.5% +$9.33K 0.2% 95
2024
Q4
$1.83M Sell
21,272
-4,816
-18% -$521K 0.25% 78
2024
Q3
$3.11M Buy
26,088
+2,509
+11% +$335K 0.4% 49
2024
Q2
$3.37M Buy
23,579
+341
+1% +$45.2K 0.53% 37
2024
Q1
$2.98M Buy
23,238
+743
+3% +$88.4K 0.52% 39
2023
Q4
$2.33M Buy
22,495
+17
+0.1% +$1.68K 0.5% 40
2023
Q3
$2.04M Sell
22,478
-314
-1% -$27.7K 0.51% 39
2023
Q2
$1.84M Buy
22,792
+180
+0.8% +$14.7K 0.46% 43
2023
Q1
$1.8M Sell
22,612
-38
-0.2% -$2.69K 0.53% 40
2022
Q4
$1.53M Buy
22,650
+780
+4% +$45.7K 0.5% 47
2022
Q3
$1.22M Hold
21,870
0.48% 44
2022
Q2
$1.22M Buy
21,870
+996
+5% +$55.3K 0.48% 44
2022
Q1
$1.17M Hold
20,874
0.42% 54
2021
Q4
$1.17M Buy
20,874
+490
+2% +$26.5K 0.42% 54
2021
Q3
$979K Buy
20,384
+2,416
+13% +$117K 0.41% 57
2021
Q2
$753K Buy
17,968
+156
+0.9% +$6.05K 0.34% 77
2021
Q1
$600K Sell
17,812
-2,792
-14% -$99.4K 0.3% 90
2020
Q4
$720K Buy
20,604
+148
+0.7% +$5.12K 0.38% 75
2020
Q3
$710K Sell
20,456
-246
-1% -$8.2K 0.45% 62
2020
Q2
$678K Buy
20,702
+360
+2% +$11.5K 0.47% 59
2020
Q1
$612K Buy
20,342
+584
+3% +$17.4K 0.57% 48
2019
Q4
$572K Buy
19,758
+2,110
+12% +$58.4K 0.44% 66
2019
Q3
$456K Buy
17,648
+48
+0.3% +$1.21K 0.4% 73
2019
Q2
$449K Buy
17,600
+316
+2% +$7.81K 0.41% 70
2019
Q1
$452K Sell
17,284
-288
-2% -$7.08K 0.45% 67
2018
Q4
$414K Buy
+17,572
New +$390K 0.33% 71

Other funds holding NVO

Claro Advisors's NVO Position: Q1 2026 in Review

Claro Advisors increased its Novo Nordisk (NVO) stake by 11% in Q1 2026, buying an estimated $108K and bringing the position to 23,201 shares worth $853K. The position accounts for 0.1% of the portfolio, ranked #167.

Claro Advisors first reported a position in NVO in Q4 2018 and has held it in 30 quarters since. The position peaked at $3.37M in Q2 2024. 1,273 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Claro Advisors held 23,201 shares of Novo Nordisk worth $853K as of Q1 2026.
  • Claro Advisors bought 2,282 Novo Nordisk shares in Q1 2026, an estimated $108K.
  • Novo Nordisk made up 0.1% of Claro Advisors's portfolio in Q1 2026, its #167 holding.
  • Claro Advisors first reported a position in Novo Nordisk in Q4 2018 and has held it in 30 quarters since.
  • Claro Advisors's Novo Nordisk position peaked at $3.37M in Q2 2024.
  • 1,273 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Claro Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.